Type 2 diabetes Trials in Dallas, United States
Conditions / Type 2 diabetes / Dallas, United States
Type 2 diabetes is a medical condition with active clinical research programs worldwide.
101 total trials for this combination
Showing top 10 of 101 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05872620 | A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT05929079 | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06972472 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | RECRUITING | PHASE3 |
| NCT06926842 | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06945419 | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | RECRUITING | — |
| NCT06993792 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | ACTIVE_NOT_RECRUITING | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT04657003 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | COMPLETED | PHASE3 |
| NCT02019264 | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | COMPLETED | PHASE4 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |